6 terminated, 5 completed, 4 recruiting, 3 active not recruiting. 14 Phase 2, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 4, Active not recruiting 3, Completed 3, Recruiting 3, Enrolling by invitation 1 |
| Phase 3 | 5 | Completed 2, Terminated 2, Recruiting 1 |
Follow Immunovant Sciences GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) IMVT-1402 - Graves' Disease | Phase 2 | Enrolling by invitation | Immunovant Sciences GmbH | 372 | 2026-01-26 | 2026-09-29 |
| An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Batoclimab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 26 | 2025-08-28 | 2026-08-11 |
| Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity IMVT-1402, Placebo - Primary Sjögren's Syndrome | Phase 2 | Active not recruiting | Immunovant Sciences GmbH | 180 | 2025-06-30 | 2026-09-10 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 210 | 2025-06-19 | 2026-08-25 |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis IMVT-1402, Placebo - Generalized Myasthenia Gravis | Phase 3 | Recruiting | Immunovant Sciences GmbH | 231 | 2025-05-27 | 2026-07-30 |
| Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Imeroprubart, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Recruiting | Immunovant Sciences GmbH | 162 | 2025-03-18 | 2026-09-30 |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) IMVT-1402, Placebo - Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 2 | Active not recruiting | Immunovant Sciences GmbH | 56 | 2025-02-19 | 2026-08-28 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis IMVT-1402, Placebo - Rheumatoid Arthritis | Phase 2 | Active not recruiting | Immunovant Sciences GmbH | 120 | 2025-01-10 | 2026-04-22 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 240 | 2024-12-17 | 2026-08-25 |
| A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease IMVT-1401 (batoclimab) - Graves Disease | Phase 2 | Completed | Immunovant Sciences GmbH | 32 | 2023-05-15 | 2026-08-13 |
| Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Batoclimab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Immunovant Sciences GmbH | 86 | 2023-01-05 | 2026-04-01 |
| To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 94 | 2022-12-15 | 2026-08-11 |
| Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Batoclimab, Placebo - Thyroid Eye Disease | Phase 3 | Completed | Immunovant Sciences GmbH | 114 | 2022-11-23 | 2025-12-03 |
| Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Observational cohort study, Batoclimab - Thyroid Eye Disease | Phase 3 | Terminated | Immunovant Sciences GmbH | 109 | 2022-11-06 | 2026-04-29 |
| Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC - Generalized Myasthenia Gravis | Phase 3 | Terminated | Immunovant Sciences GmbH | 233 | 2022-06-27 | 2026-09-14 |
| To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). RVT-1401 680 mg/weekly, RVT-1401 340 mg/weekly - Warm Autoimmune Hemolytic Anemia | Phase 2 | Terminated | Immunovant Sciences GmbH | 5 | 2020-08-11 | 2022-07-28 |
| ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection) - Graves' Ophthalmopathy (GO) | Phase 2 | Terminated | Immunovant Sciences GmbH | 65 | 2019-07-23 | 2022-09-22 |
| A Study of RVT-1401 in Myasthenia Gravis (MG) Patients RVT-1401, Placebo - Myasthenia Gravis | Phase 2 | Completed | Immunovant Sciences GmbH | 17 | 2019-05-21 | 2023-12-20 |
| Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) RVT-1401 - Graves' Ophthalmopathy | Phase 2 | Completed | Immunovant Sciences GmbH | 7 | 2019-04-22 | 2022-01-24 |
Autoimmune Diseases (7) · Graves Ophthalmopathy (5) · Graves Disease (4) · Myasthenia Gravis (3) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3) · Hyperthyroidism (2) · Arthritis, Rheumatoid (1) · Lupus Erythematosus, Cutaneous (1) · Lupus Erythematosus, Discoid (1)
United States (17) · Germany (13) · Poland (13) · Spain (13) · United Kingdom (13) · Italy (11) · Georgia (9) · Hungary (9) · Argentina (8) · Canada (8) · Greece (7) · Romania (7) · Belgium (6) · Bulgaria (6) · Serbia (6)
2025 (2)